Alector halves staff after GSK-partnered antibody flops phase 3 dementia trial
Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with a variety of frontotemporal dementia (FTD). In the pivot away from latozinemab,…